## Jeffrey M Drazen

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/8481456/publications.pdf

Version: 2024-02-01

93 papers 7,631 citations

71102 41 h-index 51608 86 g-index

94 all docs 94 docs citations

times ranked

94

7742 citing authors

#	Article	IF	CITATIONS
1	Global Initiative for Asthma Strategy 2021. Respirology, 2022, 27, 14-35.	2.3	31
2	Global Initiative for Asthma Strategy 2021: executive summary and rationale for key changes. European Respiratory Journal, 2022, 59, 2102730.	6.7	218
3	Global Initiative for Asthma Strategy 2021: Executive Summary and Rationale for Key Changes. American Journal of Respiratory and Critical Care Medicine, 2022, 205, 17-35.	5.6	196
4	Global Initiative for Asthma Strategy 2021. Executive Summary and Rationale for Key Changes. Archivos De Bronconeumologia, 2022, 58, 35-51.	0.8	31
5	Expression of Concern: Beltrami AP et al. Evidence That Human Cardiac Myocytes Divide after Myocardial Infarction. N Engl J Med 2001;344:1750-7 and Quaini F et al. Chimerism of the Transplanted Heart. N Engl J Med 2002;346:5-15 New England Journal of Medicine, 2018, 379, 1870-1870.	27.0	4
6	New Biologics for Asthma. New England Journal of Medicine, 2018, 378, 2533-2534.	27.0	34
7	Data Sharing Statements for Clinical Trials: A Requirement of the International Committee of Medical Journal Editors. Journal of Korean Medical Science, 2017, 32, 1051.	2.5	9
8	Ebola and Quarantine. New England Journal of Medicine, 2014, 371, 2029-2030.	27.0	87
9	High-Frequency Oscillatory Ventilation on Shaky Ground. New England Journal of Medicine, 2013, 368, 863-865.	27.0	55
10	Informed Consent and SUPPORT. New England Journal of Medicine, 2013, 368, 1929-1931.	27.0	67
11	Compounding Errors. New England Journal of Medicine, 2012, 367, 2436-2437.	27.0	18
12	Believe the Data. New England Journal of Medicine, 2012, 367, 1152-1153.	27.0	23
13	Transparency for Clinical Trials â€" The TEST Act. New England Journal of Medicine, 2012, 367, 863-864.	27.0	30
14	A Glimpse of the Next 100 Years in Medicine. New England Journal of Medicine, 2012, 367, 2538-2539.	27.0	70
15	A Patient with Asthma Seeks Medical Advice in 1828, 1928, and 2012. New England Journal of Medicine, 2012, 366, 827-834.	27.0	34
16	Asthma: The paradox of heterogeneity. Journal of Allergy and Clinical Immunology, 2012, 129, 1200-1201.	2.9	21
17	The Politics of Emergency Contraception. New England Journal of Medicine, 2012, 366, 101-102.	27.0	17
18	Patient Organizations and Research on Rare Diseases. New England Journal of Medicine, 2011, 364, 1670-1671.	27.0	42

#	Article	IF	CITATIONS
19	Asthma Treatment Guidelines Meet the Real World. New England Journal of Medicine, 2011, 364, 1769-1770.	27.0	34
20	Considering Recertification. New England Journal of Medicine, 2010, 362, 946-947.	27.0	42
21	Choosing Asthma Step-up Care. New England Journal of Medicine, 2010, 362, 1042-1043.	27.0	27
22	Don't Mess with the DSMB. New England Journal of Medicine, 2010, 363, 477-478.	27.0	38
23	Sibutramine — Another Flawed Diet Pill. New England Journal of Medicine, 2010, 363, 972-974.	27.0	40
24	The Growth of Hospitalists and the Changing Face of Primary Care. New England Journal of Medicine, 2009, 360, 1141-1143.	27.0	26
25	Risks of Long-Acting Beta-Agonists in Achieving Asthma Control. New England Journal of Medicine, 2009, 360, 1671-1672.	27.0	86
26	The Medical Device Safety Act of 2009. New England Journal of Medicine, 2009, 360, 1550-1551.	27.0	28
27	Genetics and pharmacogenetics of the leukotriene pathway. Journal of Allergy and Clinical Immunology, 2009, 124, 422-427.	2.9	69
28	Letting the Genome out of the Bottle — Will We Get Our Wish?. New England Journal of Medicine, 2008, 358, 105-107.	27.0	351
29	Cholesterol Lowering and Ezetimibe. New England Journal of Medicine, 2008, 358, 1507-1508.	27.0	57
30	Physicians and Execution. New England Journal of Medicine, 2008, 358, 403-404.	27.0	17
31	Full Disclosure and the Funding of Biomedical Research. New England Journal of Medicine, 2008, 358, 1850-1851.	27.0	46
32	Cardiac Transplantation in Infants. New England Journal of Medicine, 2008, 359, 749-750.	27.0	24
33	Why Doctors Should Worry about Preemption. New England Journal of Medicine, 2008, 359, 1-3.	27.0	94
34	Rosiglitazone â€" Continued Uncertainty about Safety. New England Journal of Medicine, 2007, 357, 63-64.	27.0	49
35	Salvation by Registration. New England Journal of Medicine, 2007, 356, 184-185.	27.0	19
36	Open Clinical Trials. New England Journal of Medicine, 2007, 357, 1756-1757.	27.0	23

#	Article	IF	CITATIONS
37	Human Papillomavirus Vaccine â€" Opportunity and Challenge. New England Journal of Medicine, 2007, 356, 1990-1991.	27.0	39
38	Drug-Eluting Coronary Stents — Promise and Uncertainty. New England Journal of Medicine, 2007, 356, 1059-1060.	27.0	87
39	Statistics in Medicine — Reporting of Subgroup Analyses in Clinical Trials. New England Journal of Medicine, 2007, 357, 2189-2194.	27.0	1,154
40	CHRONIC EFFECTS OF MECHANICAL FORCE ON AIRWAYS. Annual Review of Physiology, 2006, 68, 563-583.	13.1	125
41	COX-2 Inhibitors â€" A Lesson in Unexpected Problems. New England Journal of Medicine, 2005, 352, 1131-1132.	27.0	186
42	Trial Registration Report Card. New England Journal of Medicine, 2005, 353, 2809-2811.	27.0	30
43	A Sad Day for Science at the FDA. New England Journal of Medicine, 2005, 353, 1197-1199.	27.0	29
44	Asthma. American Journal of Respiratory and Critical Care Medicine, 2005, 171, 1202-1208.	5 <b>.</b> 6	78
45	Registry Research and Medical Privacy. New England Journal of Medicine, 2004, 350, 1452-1453.	27.0	85
46	Public Access to Biomedical Research. New England Journal of Medicine, 2004, 351, 1343-1343.	27.0	12
47	Awake and Informed. New England Journal of Medicine, 2004, 351, 1884-1884.	27.0	49
48	Decisions at the End of Life. New England Journal of Medicine, 2003, 349, 1109-1110.	27.0	30
49	Controlling Research Trials. New England Journal of Medicine, 2003, 348, 1377-1380.	27.0	35
50	Immunostimulatory DNA for Asthma. American Journal of Respiratory Cell and Molecular Biology, 2003, 28, 645-647.	2.9	22
51	Guidance Concerning Surgery for Emphysema. New England Journal of Medicine, 2003, 348, 2134-2136.	27.0	25
52	Legislative Myopia on Stem Cells. New England Journal of Medicine, 2003, 349, 300-300.	27.0	13
53	SARS, the Internet, and the Journal. New England Journal of Medicine, 2003, 348, 2029-2029.	27.0	14
54	Inappropriate Advertising of Dietary Supplements. New England Journal of Medicine, 2003, 348, 777-778.	27.0	39

#	Article	IF	CITATIONS
55	SARS â€" Looking Back over the First 100 Days. New England Journal of Medicine, 2003, 349, 319-320.	27.0	49
56	Î <sup>2</sup> -Agonists and asthma: too much of a good thing?. Journal of Clinical Investigation, 2003, 112, 495-497.	8.2	35
57	Pharmacogenetics of Asthma. American Journal of Respiratory and Critical Care Medicine, 2002, 165, 861-866.	5.6	123
58	The Consumer and the Learned Intermediary in Health Care. New England Journal of Medicine, 2002, 346, 523-524.	27.0	22
59	Sleep Apnea Syndrome. New England Journal of Medicine, 2002, 346, 390-390.	27.0	16
60	Smallpox and Bioterrorism. New England Journal of Medicine, 2002, 346, 1262-1263.	27.0	25
61	Financial Associations of Authors. New England Journal of Medicine, 2002, 346, 1901-1902.	27.0	170
62	Rethinking Medical Training â€" The Critical Work Ahead. New England Journal of Medicine, 2002, 347, 1271-1272.	27.0	55
63	Institutions, Contracts, and Academic Freedom. New England Journal of Medicine, 2002, 347, 1362-1363.	27.0	56
64	Mucosal Folding in Biologic Vessels. Journal of Biomechanical Engineering, 2002, 124, 334-341.	1.3	43
65	Ventilation with Small Tidal Volumes. New England Journal of Medicine, 2002, 347, 630-631.	27.0	104
66	Inherit the wheeze. Nature, 2002, 418, 383-384.	27.8	25
67	Multi-pronged inhibition of airway hyper-responsiveness and inflammation by lipoxin A4. Nature Medicine, 2002, 8, 1018-1023.	30.7	346
68	Designing and Funding Clinical Trials of Novel Therapies. New England Journal of Medicine, 2001, 344, 762-763.	27.0	22
69	AIDS â€" Will the Next 20 Years Be Different?. New England Journal of Medicine, 2001, 344, 1781-1782.	27.0	17
70	Tracking the Peer-Review Process. New England Journal of Medicine, 2000, 343, 1485-1486.	27.0	14
71	To Protect Those Who Serve. New England Journal of Medicine, 2000, 343, 1643-1645.	27.0	51
72	Urinary leukotriene (LT) E4 in adolescents with dysmenorrhea: a pilot study. Journal of Adolescent Health, 2000, 27, 151-154.	2.5	30

#	Article	IF	CITATIONS
73	Recurrent Panniculitis in a Man With Asthma Receiving Treatment With Leukotriene-Modifying Agents. Mayo Clinic Proceedings, 2000, 75, 643-645.	3.0	17
74	Genetic Determinants of 5–Lipoxygenase Transcription. International Archives of Allergy and Immunology, 1999, 118, 275-278.	2.1	22
75	Treatment of Asthma with Drugs Modifying the Leukotriene Pathway. New England Journal of Medicine, 1999, 340, 197-206.	27.0	778
76	Leukotriene Modifiers and Churg-Strauss Syndrome. Drug Safety, 1999, 21, 241-251.	3.2	76
77	The Biology of 5-Lipoxygenase: Function, Structure, and Regulatory Mechanisms. Proceedings of the Association of American Physicians, 1999, 111, 525-536.	2.0	43
78	Asthma Therapy with Agents Preventing Leukotriene Synthesis or Action. Proceedings of the Association of American Physicians, 1999, 111, 547-559.	2.0	32
79	Should Antileukotriene Therapies Be Used Instead of Inhaled Corticosteroids in Asthma?. American Journal of Respiratory and Critical Care Medicine, 1998, 158, 1697-1698.	5.6	19
80	Genetics of Native Airway Responsiveness in Mice. American Journal of Respiratory and Critical Care Medicine, 1997, 156, S82-S88.	5.6	22
81	Treatment of Chronic Stable Asthma with Drugs Active on the 5-Lipoxygenase Pathway. International Archives of Allergy and Immunology, 1995, 107, 319-320.	2.1	16
82	Treating Mild Asthma - When Are Inhaled Steroids Indicated?. New England Journal of Medicine, 1994, 331, 737-739.	27.0	24
83	Active anaphylaxis in IgE-deficient mice. Nature, 1994, 370, 367-370.	27.8	407
84	Agonist-induced lipoxin A4 generation: Detection by a novel lipoxin A4-ELISA. Lipids, 1993, 28, 1047-1053.	1.7	54
85	Models of Airway Hyperresponsiveness. The American Review of Respiratory Disease, 1990, 141, 253-257.	2.9	54
86	Effect of a Leukotriene Antagonist, LY171883, on Cold Air-induced Bronchoconstriction in Asthmatics. The American Review of Respiratory Disease, 1989, 140, 1348-1353.	2.9	82
87	Heterogeneity of Leukotriene C4Production by Eosinophils from Asthmatic and from Normal Subjects. The American Review of Respiratory Disease, 1988, 138, 799-804.	2.9	48
88	Transition from Normal to Hypersecretory Bronchial Mucus in a Canine Model of Bronchitis: Changes in Yield and Composition. Experimental Lung Research, 1988, 14, 101-120.	1.2	25
89	Leukotrienes and Airway Responses. The American Review of Respiratory Disease, 1987, 136, 985-998.	2.9	279
90	Effect of nifedipine on constriction of human tracheal strips <i>in vitro</i> . British Journal of Pharmacology, 1983, 78, 687-691.	5 <b>.</b> 4	59

#	Article	IF	CITATIONS
91	A review of recent contributions on biologically active products of arachidonate conversion. International Journal of Immunopharmacology, 1982, 4, 85-90.	1.1	38
92	In Vivo Demonstration of Nonadrenergic Inhibitory Innervation of the Guinea Pig Trachea. Journal of Clinical Investigation, 1980, 65, 314-320.	8.2	91
93	Effects of Intravenous Administration of Slow-Reacting Substance of Anaphylaxis, Histamine, Bradykinin, and Prostaglandin F2α on Pulmonary Mechanics in the Guinea Pig. Journal of Clinical Investigation, 1974, 53, 1679-1685.	8.2	126